Huang Wei-Ting, Larsson Mikael, Lee Yi-Chi, Liu Dean-Mo, Chiou Guang-Yuh
Department of Materials Science and Engineering, National Chiao Tung University, 1001 Ta-Hseuh Road, Hsinchu City 300, Taiwan, ROC.
School of Energy and Resources, University College London, 220 Victoria Square, Adelaide, SA 5000, Australia; Future Industries Institute, University of South Australia, Mawson Lakes Campus, SA 5095, Australia.
Eur J Pharm Biopharm. 2016 Dec;109:165-173. doi: 10.1016/j.ejpb.2016.10.014. Epub 2016 Oct 25.
Lung cancer kills more humans than any other cancer and multidrug resistance (MDR) in cancer stem-like cells (CSC) is emerging as a reason for failed treatments. One concept that addresses this root cause of treatment failure is the utilization of nanoparticles to simultaneously deliver dual drugs to cancer cells with synergistic performance, easy to envision - hard to achieve. (1) It is challenging to simultaneously load drugs of highly different physicochemical properties into one nanoparticle, (2) release kinetics may differ between drugs and (3) general requirements for biomedical nanoparticles apply. Here self-assembled nanoparticles of amphiphilic carboxymethyl-hexanoyl chitosan (CHC) were shown to present nano-microenvironments enabling simultaneous loading of hydrophilic and hydrophobic drugs. This was expanded into a dual-drug nano-delivery system to treat lung CSC. CHC nanoparticles were loaded/chemically modified with the anticancer drug cisplatin and the MDR-suppressing Chinese herbal extract demethoxycurcumin, followed by biofunctionalization with CD133 antibody for enhanced uptake by lung CSC, all in a feasible one-pot preparation. The nanoparticles were characterized with regard to chemistry, size, zeta potential and drug loading/release. Biofunctionalized and non-functionalized nanoparticles were investigated for uptake by lung CSC. Subsequently the cytotoxicity of single and dual drugs, free in solution or in nanoparticles, was evaluated against lung CSC at different doses. From the dose response at different concentrations the degree of synergy was determined through Chou-Talalay's Plot. The biofunctionalized nanoparticles promoted synergistic effects between the drugs and were highly effective against MDR lung CSC. The efficacy and feasible one-pot preparation suggests preclinical studies using relevant disease models to be justified.
肺癌导致的死亡人数比其他任何癌症都多,癌症干细胞(CSC)中的多药耐药性(MDR)正成为治疗失败的一个原因。解决治疗失败这一根源问题的一个概念是利用纳米颗粒同时将具有协同性能的两种药物递送至癌细胞,这说起来容易做起来难。(1)将物理化学性质差异极大的药物同时载入一个纳米颗粒具有挑战性,(2)不同药物的释放动力学可能不同,以及(3)生物医学纳米颗粒有通用要求。在这里,两亲性羧甲基己酰壳聚糖(CHC)自组装纳米颗粒被证明能提供纳米微环境,实现亲水性和疏水性药物的同时载入。这被扩展为一种双药纳米递送系统来治疗肺癌干细胞。CHC纳米颗粒用抗癌药物顺铂和抑制多药耐药性的中药提取物去甲氧基姜黄素进行载入/化学修饰,随后用CD133抗体进行生物功能化,以增强肺癌干细胞的摄取,所有这些都在一个可行的一锅法制备中完成。对纳米颗粒进行了化学、尺寸、zeta电位以及药物载入/释放方面的表征。研究了生物功能化和未功能化纳米颗粒被肺癌干细胞摄取的情况。随后,评估了溶液中或纳米颗粒中的单药和双药在不同剂量下对肺癌干细胞的细胞毒性。根据不同浓度下的剂量反应,通过Chou-Talalay图确定协同程度。生物功能化纳米颗粒促进了药物之间的协同作用,对多药耐药性肺癌干细胞非常有效。其有效性和可行的一锅法制备表明使用相关疾病模型进行临床前研究是合理的。